Advanced Cancer Immunotherapy via SMARCAL1 Blockade Using a Glucose-Responsive CRISPR Nanovaccine

Area of Science:

• Biomedical Engineering
• Immunology
• Gene Therapy

Background:

• Cancer immunotherapy faces challenges from tumor-induced immunosuppression, including T-cell exhaustion mediated by programmed death-ligand 1 (PD-L1).
• The stimulator of interferon genes (STING) pathway is crucial for antitumor immunity, but its activation can paradoxically promote immunosuppression via PD-L1.
• Tumor-specific factors like SMARCAL1 further complicate effective cancer immune responses.

Purpose of the Study:

• To develop a novel glucose-responsive CRISPR nanovaccine for cancer immunotherapy.
• To enhance STING signaling while simultaneously inhibiting interferon-mediated immunosuppressive feedback.
• To overcome tumor immunosuppressive factors like SMARCAL1 for improved antitumor immunity.

Main Methods:

• Formulation of a bimetallic zeolitic imidazolate framework encapsulating glucose oxidase (GOx) and CRISPR-SMARCAL1 gene-editing plasmids.
• Utilizing dual enzyme-driven cascade reactions (peroxidase and GOx) to generate reactive oxygen species (ROS) and gluconic acid for nanovaccine activation.
• Employing CRISPR-mediated gene editing to silence SMARCAL1 within the tumor microenvironment.

Main Results:

• The nanovaccine effectively silenced SMARCAL1, enhancing STING pathway activity.
• Inhibition of PD-L1 expression was achieved, counteracting interferon-mediated immunosuppression.
• ROS and released zinc ions further activated the STING pathway, promoting dendritic cell maturation and immune activation.

Conclusions:

• The developed glucose-responsive CRISPR nanovaccine demonstrates a promising strategy for bolstering antitumor immunity.
• This approach effectively integrates gene editing with nanovaccine technology to overcome key immunosuppressive mechanisms in cancer.
• The study highlights the potential of in situ, enzyme-driven CRISPR nanovaccination for advancing cancer immunotherapy.